ZOE Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistently strong operating cash flow and high free cash conversion provide durable financial flexibility. Over the next 2–6 months this supports R&D, bolt‑on M&A, dividends and buybacks while cushioning earnings volatility and enabling prioritized capital allocation even if revenue lags.
High Margins & ProfitabilityVery healthy margins across the P&L indicate structural pricing power and efficient cost base. Sustained high gross and operating margins give the company headroom to absorb pocketed price realization or mix shifts while funding innovation and maintaining free cash flow over coming quarters.
Portfolio Diversification (Livestock & Diagnostics)Robust growth in livestock and diagnostics reduces reliance on companion-animal cycles. These segments show sustainable mid‑single to high‑single digit secular demand and strategic acquisitions/validation expand recurring revenue streams, improving structural revenue stability over months.
Bears Say
Companion Animal Demand WeaknessThe largest franchise faces persistent weaker clinic visits and heightened competition, which structurally reduces volume and pricing power. As companion remains core, prolonged softness can materially depress top‑line and slow product launches' ramp over the next several quarters.
Price Realization & Gross‑to‑net HeadwindsEmbedded gross‑to‑net and rebate investments signal structural pressure on realized prices from generics and promotions. Sustained negative price realization compresses margins and cash flow, limiting reinvestment capacity and forcing ongoing cost actions to protect profitability.
Balance‑sheet Volatility And Declining EquityMarked deterioration in equity and volatile leverage history reduce financial cushion and complicate trend assessment. This raises refinancing and capital‑allocation risk, potentially constraining M&A, buybacks or defensive investment if adverse scenarios persist over the medium term.
Zoetis News
ZOE FAQ
What was Zoetis’s price range in the past 12 months?
Currently, no data Available
What is Zoetis’s market cap?
Zoetis’s market cap is CHF26.21B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Nov 11, 2026 which is in 93 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Aug 06, 2026. The company reported CHF1.511 earnings per share for the quarter, beating the consensus estimate of CHF1.496 by CHF0.015.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis does not currently pay dividends.
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.29.
How many shares outstanding does Zoetis have?
Currently, no data Available
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of CHF1.511 in its last earnings report, beating expectations of CHF1.496. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in CH:ZOE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF74.57 (― Upside)
CHF74.57 (― Upside)
Blogger Sentiment
Bullish
CH:ZOE Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF714.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 10%
Bearish news 90%
Bearish news 90%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.13%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
ZOE Company Deck
ZOE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mixed picture: clear strengths in Livestock, Diagnostics, international and continued pipeline progress, plus disciplined cost and capital return actions. However, material weakness in core Companion Animal markets—especially U.S. Dermatology and parasiticides—intensified competitive promotional activity, declining clinic visits, price realization pressure from gross-to-net investments, generics, and a meaningful downward revision to full-year guidance. While the portfolio diversification and cost actions provide resilience, the near-term trends in the company’s largest franchise create significant headwinds.View all CH:ZOE earnings summariesZOE Revenue Breakdown
20.69% Vaccines
24.73% Parasiticides
18.53% Dermatology
10.94% Anti-infectives
8.87% Pain and sedation
7.36% Other pharmaceuticals
4.58% Animal health diagnostics
2.78% Other non-pharmaceuticals
0.29% Medicated feed additives
1.23% Contract manufacturing & human health
